Suvarna Garge (Editor)

Avanafil

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Trade names
  
Stendra

Routes of administration
  
Oral

Molar mass
  
483.951 g/mol

License data
  
US FDA: Avanafil

ATC code
  
G04BE10 (WHO)

Avanafil

Pregnancy category
  
US: C (Risk not ruled out)

Legal status
  
UK: POM (Prescription only) US: ℞-only

Which medication is most effective for erectile dysfunction by dr williams edquestions


Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. In July 2013 Vivus announced partnership with Menarini Group, which will commercialise and promote Spedra in over 40 European countries plus Australia and New Zealand. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30–45 minutes. About two-thirds of the participants were able to engage in sexual activity within 15 minutes.

Contents

Synthesis

Avanafil can be synthesized from a benzylamine derivative and a pyrimidine derivative:

References

Avanafil Wikipedia